Skip to Main Content

Author Details

Christopher A Maher
Washington University in St Louis
2006
98
50
PMIDPaper TitleJournal TitlePublished Year
37400526Genetic characterization of primary and metastatic high-grade serous ovarian cancer tumors reveals distinct features associated with survival.Commun Biol2023
38023733Single-cell transcriptomics reveals long noncoding RNAs associated with tumor biology and the microenvironment in pancreatic cancer.NAR Cancer2023
37549060PACT: a pipeline for analysis of circulating tumor DNA.Bioinformatics2023
37213253Characterization of cell-type specific circular RNAs associated with colorectal cancer metastasis.NAR Cancer2023
37400526Genetic characterization of primary and metastatic high-grade serous ovarian cancer tumors reveals distinct features associated with survival.Commun Biol2023
37275273CrypticProteinDB: an integrated database of proteome and immunopeptidome derived non-canonical cancer proteins.NAR Cancer2023
36949070Integrated analysis of genomic and transcriptomic data for the discovery of splice-associated variants in cancer.Nat Commun2023
37370778Large, Nested Variant of Urothelial Carcinoma Is Enriched with Activating Mutations in Fibroblast Growth Factor Receptor-3 among Other Targetable Mutations.Cancers (Basel)2023
38023733Single-cell transcriptomics reveals long noncoding RNAs associated with tumor biology and the microenvironment in pancreatic cancer.NAR Cancer2023
37549060PACT: a pipeline for analysis of circulating tumor DNA.Bioinformatics2023
36949070Integrated analysis of genomic and transcriptomic data for the discovery of splice-associated variants in cancer.Nat Commun2023
37213253Characterization of cell-type specific circular RNAs associated with colorectal cancer metastasis.NAR Cancer2023
37275273CrypticProteinDB: an integrated database of proteome and immunopeptidome derived non-canonical cancer proteins.NAR Cancer2023
37370778Large, Nested Variant of Urothelial Carcinoma Is Enriched with Activating Mutations in Fibroblast Growth Factor Receptor-3 among Other Targetable Mutations.Cancers (Basel)2023
34740892Loss of Long Noncoding RNA <i>NXTAR</i> in Prostate Cancer Augments Androgen Receptor Expression and Enzalutamide Resistance.Cancer Res2022
36251389The 5-Hydroxymethylcytosine Landscape of Prostate Cancer.Cancer Res2022
35418131LINC00355 regulates p27<sup>KIP</sup> expression by binding to MENIN to induce proliferation in late-stage relapse breast cancer.NPJ Breast Cancer2022
35852383Pan-Cancer Analysis Reveals Recurrent BCAR4 Gene Fusions across Solid Tumors.Mol Cancer Res2022
34740892Loss of Long Noncoding RNA <i>NXTAR</i> in Prostate Cancer Augments Androgen Receptor Expression and Enzalutamide Resistance.Cancer Res2022
35076605<i>DANSR</i>: A Tool for the Detection of Annotated and Novel Small RNAs.Noncoding RNA2022
35852383Pan-Cancer Analysis Reveals Recurrent BCAR4 Gene Fusions across Solid Tumors.Mol Cancer Res2022
35418131LINC00355 regulates p27<sup>KIP</sup> expression by binding to MENIN to induce proliferation in late-stage relapse breast cancer.NPJ Breast Cancer2022
36251389The 5-Hydroxymethylcytosine Landscape of Prostate Cancer.Cancer Res2022
35076605<i>DANSR</i>: A Tool for the Detection of Annotated and Novel Small RNAs.Noncoding RNA2022
34256279Phase 1 study combining alisertib with nab-paclitaxel in patients with advanced solid malignancies.Eur J Cancer2021
33807183Long, Noncoding RNA Dysregulation in Glioblastoma.Cancers (Basel)2021
33953369Long noncoding RNAs in cancer metastasis.Nat Rev Cancer2021
34146471A community challenge to evaluate RNA-seq, fusion detection, and isoform quantification methods for cancer discovery.Cell Syst2021
34256279Phase 1 study combining alisertib with nab-paclitaxel in patients with advanced solid malignancies.Eur J Cancer2021
34250420ctDNA MRD Detection and Personalized Oncogenomic Analysis in Oligometastatic Colorectal Cancer From Plasma and Urine.JCO Precis Oncol2021
33807183Long, Noncoding RNA Dysregulation in Glioblastoma.Cancers (Basel)2021
34250420ctDNA MRD Detection and Personalized Oncogenomic Analysis in Oligometastatic Colorectal Cancer From Plasma and Urine.JCO Precis Oncol2021
34146471A community challenge to evaluate RNA-seq, fusion detection, and isoform quantification methods for cancer discovery.Cell Syst2021
33953369Long noncoding RNAs in cancer metastasis.Nat Rev Cancer2021
31383964Sclerosing epithelioid mesenchymal neoplasm of the pancreas - a proposed new entity.Mod Pathol2020
32358485Long non-coding RNA RAMS11 promotes metastatic colorectal cancer progression.Nat Commun2020
32181394Long non-coding RNA <i>LCAL62 / LINC00261</i> is associated with lung adenocarcinoma prognosis.Heliyon2020
31728961Gene Fusion Discovery with INTEGRATE.Methods Mol Biol2020
31932493Diverse <i>AR</i> Gene Rearrangements Mediate Resistance to Androgen Receptor Inhibitors in Metastatic Prostate Cancer.Clin Cancer Res2020
32091043Heparin-based hydrogel scaffolding alters the transcriptomic profile and increases the chemoresistance of MDA-MB-231 triple-negative breast cancer cells.Biomater Sci2020
32985524SV-HotSpot: detection and visualization of hotspots targeted by structural variants associated with gene expression.Sci Rep2020
32803163Pan-cancer proteogenomic analysis reveals long and circular noncoding RNAs encoding peptides.NAR Cancer2020
32577507The clonal evolution of metastatic colorectal cancer.Sci Adv2020
32903952Cell-free DNA alterations in the <i>AR</i> enhancer and locus predict resistance to AR-directed therapy in patients with metastatic prostate cancer.JCO Precis Oncol2020
33335027Antibody profiling of patients with prostate cancer reveals differences in antibody signatures among disease stages.J Immunother Cancer2020
31383964Sclerosing epithelioid mesenchymal neoplasm of the pancreas - a proposed new entity.Mod Pathol2020
32091043Heparin-based hydrogel scaffolding alters the transcriptomic profile and increases the chemoresistance of MDA-MB-231 triple-negative breast cancer cells.Biomater Sci2020
31728961Gene Fusion Discovery with INTEGRATE.Methods Mol Biol2020
31932493Diverse <i>AR</i> Gene Rearrangements Mediate Resistance to Androgen Receptor Inhibitors in Metastatic Prostate Cancer.Clin Cancer Res2020
33335027Antibody profiling of patients with prostate cancer reveals differences in antibody signatures among disease stages.J Immunother Cancer2020
  • 1 - 50 of 196

Recommended Authors

Rohan Bareja
Case Western Reserve University
Career Start Year 2017
Number of shared co-authors 12
Job van Riet
Erasmus MC Cancer Institute
Career Start Year 2017
Number of shared co-authors 5
Vincent Huang
Ontario Institute for Cancer Research
Career Start Year 2016
Number of shared co-authors 28
Kimaada Allette
Icahn School of Medicine at Mount Sinai
Career Start Year 2016
Number of shared co-authors 2
Yulia Newton
University of California, Santa Cruz Genomics Institute
Career Start Year 2014
Number of shared co-authors 30
Travers Ching
Adaptive Biotechnologies
Career Start Year 2014
Number of shared co-authors 0
Daniel Vod??k
Institute for Cancer Research, Oslo University Hospital
Career Start Year 2014
Number of shared co-authors 10
Yari Ciani
University of Trento
Career Start Year 2012
Number of shared co-authors 61
Gunes Gundem
Memorial Sloan Kettering Cancer Center
Career Start Year 2010
Number of shared co-authors 8
Asha A Nair
Mayo Clinic
Career Start Year 2010
Number of shared co-authors 1
Siyuan Zheng
Greehey Children's Cancer Research Institute
Career Start Year 2007
Number of shared co-authors 15
Raj Chari
The National Institutes of Health
Career Start Year 2006
Number of shared co-authors 6
Nicola Waddell
QIMR Berghofer Medical Research Institute
Career Start Year 2006
Number of shared co-authors 26
Matti Nykter
Prostate Cancer Research Center, Tampere University and Tays Cancer Center
Career Start Year 2006
Number of shared co-authors 43
Han Liang
MD Anderson Cancer Center
Career Start Year 2005
Number of shared co-authors 19
Paul M Krzyzanowski
Ontario Institute for Cancer Research
Career Start Year 2005
Number of shared co-authors 5
Steffen Durinck
Genentech Inc.
Career Start Year 2004
Number of shared co-authors 9
Amy G Robertson
Present address: Dxige Research Inc.
Career Start Year 2003
Number of shared co-authors 42
Olivier Harismendy
University of California
Career Start Year 2003
Number of shared co-authors 3
Trevor J Pugh
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2003
Number of shared co-authors 32
Jianhua Zhang
University of Texas MD Anderson Cancer Center
Career Start Year 2003
Number of shared co-authors 16
Jianmin Wang
Roswell Park Comprehensive Cancer Center
Career Start Year 2003
Number of shared co-authors 4
Nikolaus Schultz
Memorial Sloan Kettering Cancer Center
Career Start Year 2003
Number of shared co-authors 63
Peter Van Loo
The Francis Crick Institute
Career Start Year 2003
Number of shared co-authors 11
Joel S Parker
Lineberger Cancer Center, University of North Carolina
Career Start Year 2002
Number of shared co-authors 31
Olivier Elemento
Meyer Cancer Center
Career Start Year 2002
Number of shared co-authors 54
Andrea Sboner
Institute for Computational Biomedicine
Career Start Year 2000
Number of shared co-authors 57
Gad Getz
Broad Institute of the Massachusetts Institute of Technology and Harvard
Career Start Year 2000
Number of shared co-authors 54
Yan W Asmann
Mayo Clinic
Career Start Year 2000
Number of shared co-authors 2
Luigi Marchionni
Weill-Cornell School of Medicine
Career Start Year 1989
Number of shared co-authors 62

Collaborators

Arul M Chinnaiyan
University of Michigan Medical School.
Co-authored papers 24
Jin Zhang
Washington University in St. Louis
Co-authored papers 18
Elaine R Mardis
The Ohio State University
Co-authored papers 15
Nallasivam Palanisamy
Vattikuti Urology Institute
Co-authored papers 12
Richard K Wilson
The Ohio State University
Co-authored papers 12
Xuhong Cao
Michigan Center for Translational Pathology.
Co-authored papers 11
Felix Y Feng
UCSF Medical Center-Mount Zion
Co-authored papers 11
Christopher A Miller
Washington University School of Medicine
Co-authored papers 10
Malachi Griffith
Washington University
Co-authored papers 9
Robert S Fulton
McDonnell Genome Institute, Washington University School of Medicine
Co-authored papers 9
Jason Walker
McDonnell Genome Institute, Washington University School of Medicine
Co-authored papers 8
Li Ding
McDonnell Genome Institute, Washington University School of Medicine
Co-authored papers 8
Chandan Kumar-Sinha
Co-authored papers 8
Obi L Griffith
Washington University
Co-authored papers 8
Martin E Gleave
University of British Columbia
Co-authored papers 7
Ramaswamy Govindan
Siteman Cancer Center, Washington University School of Medicine
Co-authored papers 7
David A Quigley
University of California-San Francisco
Co-authored papers 7
Timothy J Ley
Washington University School of Medicine
Co-authored papers 7
David E Larson
McDonnell Genome Institute, Washington University School of Medicine
Co-authored papers 7
Matthew J Ellis
Co-authored papers 6
Joshua F McMichael
Washington University
Co-authored papers 6
Vincent Magrini
The Ohio State University
Co-authored papers 6
Sooryanarayana Varambally
University of Alabama at Birmingham, USA O'Neal Comprehensive Cancer Center
Co-authored papers 6
Javed Siddiqui
Michigan Center for Translational Pathology, University of Michigan ann arbor
Co-authored papers 6
Robert J Lonigro
Michigan Center for Translational Pathology, University of Michigan ann arbor
Co-authored papers 6
Jorge S Reis-Filho
Memorial Sloan-Kettering Cancer Center
Co-authored papers 5
Scott A Tomlins
Rogel Cancer Center, University of Michigan Medical School ann arbor
Co-authored papers 5
Eric J Small
University of California san francisco
Co-authored papers 5
Winston Hide
Harvard Medical School
Co-authored papers 5
Dan R Robinson
Michigan Center for Translational Pathology, University of Michigan ann arbor
Co-authored papers 5
Release 1.2